Center for Interstitial Lung Diseases, University of Washington Medical Center, Division of Pulmonary, Critical Care and Sleep Medicine, Seattle, WA, USA
Eur Respir Rev. 2017 Sep 27;26(145). doi: 10.1183/16000617.0071-2017. Print 2017 Sep 30.
Over the past two and a half decades, many clinical trials have been designed to determine the safety and efficacy of pharmacotherapy for patients with idiopathic pulmonary fibrosis (IPF). However, so far, only two drugs (pirfenidone and nintedanib) have been found to have an impact on disease progression as defined by reducing the rate of decline in forced vital capacity over a year among IPF patients with mild to moderate impairment in lung function. These two drugs have been approved for treatment of IPF by regulatory agencies and are currently in clinical use worldwide. This article summarises the current landscape of pharmacotherapy for IPF and highlights the prospects and potential of new therapies that are currently being pursued in clinical trials.
在过去的 25 年中，已经设计了许多临床试验来确定针对特发性肺纤维化 (IPF) 患者的药物治疗的安全性和有效性。然而，到目前为止，只有两种药物（吡非尼酮和尼达尼布）被发现对疾病进展有影响，可降低肺功能轻度至中度受损的 IPF 患者一年内用力肺活量下降的速度。这两种药物已被监管机构批准用于治疗 IPF，目前正在全球范围内临床使用。本文总结了目前 IPF 的药物治疗现状，并强调了目前正在临床试验中探索的新疗法的前景和潜力。
